Home  > 
  Guangzhou receives Chinese approval for clinical trials of KX-02 for glioblastoma,   May 26, 2017
  GW Pharmaceuticals announces phase 3 study of Epidiolex in children with Dravet syndrome,   May 26, 2017
  OncoQuest to present phase II clinical results of Oregovomab for treatment of ovarian cancer at ASCO annual meet,   May 26, 2017
  Liquidia technologies reports positive phase 1 data of LIQ865 for post-surgical pain relief,   May 26, 2017
  Neurocrine's phase II study of Ingrezza to treat tourette syndrome fails to meet primary endpoint,   May 25, 2017
  Boehringer Ingelheim's phase III clinical data shows Spiriva Respimat improves breathing for people with asthma regardless of BMI or allergic status,   May 25, 2017
  Mallinckrodt begins patient enrollment in phase 4 study of H.P. Acthar gel for multiple sclerosis,   May 25, 2017
  New data at ATS add to the body of evidence for Roche‚Äôs Esbriet in idiopathic pulmonary fibrosis,   May 25, 2017
  Otsuka reports positive top-line results from phase 3 trial of tolvaptan in adult patients with ADPKD,   May 24, 2017
  NeuroVive to continue NeuroSTAT clinical development after positive outcome in preclinical & clinical TBI studies,   May 24, 2017
  ORYX announ ces positive findings from oncolytic virus ParvOryx in combo with immuno-oncology drugs,   May 24, 2017
  AstraZeneca phase IIIb/IV EXSCEL of Bydureon meets primary endpoint,   May 24, 2017
  AstraZeneca presents positive data from phase III ZONDA trial for benralizumab at ATS 2017 international congress,   May 23, 2017
  Amgen, UCB announce positive results from phase 3 ARCH study of Evenity in postmenopausal women with osteoporosis,   May 23, 2017
  Bonesupport begins enrollment in FORTIFY trial with Cerament G, a novel injectable, antibiotic-eluting bone graft substitute,   May 23, 2017
  Amgen presents positive data from Repatha cardiovascular outcomes trial at 2017 NLA scientific sessions,   May 22, 2017
  Merus reports positive results from MCLA-128 phase 1/2 study in metastatic breast cancer,   May 20, 2017
  MorphoSys completes first part of phase 1 study with lanthipeptide MOR107,   May 20, 2017
  Janssen Biotech plans to start new studies of daratumumab in multiple myeloma and amyloidosis,   May 20, 2017
  Omeros reports additional positive results from phase 2 trial of OMS721 to treat kidney disorders,   May 19, 2017

Copyright © 2016 Saffron Media Pvt. Ltd |